Meeting
2016 ASCO Annual Meeting
Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced adrenocortical carcinoma from the JAVELIN solid tumor phase Ib trial: Safety and clinical activity.
Authors
Christophe Le Tourneau
Institut Curie, Paris, France
Christophe Le Tourneau , Christopher J. Hoimes , Corrine Zarwan , Deborah Jean Lee Wong , Sebastian Bauer , Martin Wermke , Rainer Claus , Kevin M. Chin , Anja von Heydebreck , Jean-Marie Cuillerot , James L. Gulley
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Genitourinary (Nonprostate) Cancer
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Other GU Kidney and Bladder Cancer
Clinical Trial Registration Number
NCT01772004
Citation
J Clin Oncol 34, 2016 (suppl; abstr 4516)
DOI
10.1200/JCO.2016.34.15_suppl.4516
Abstract #
4516
Poster Bd #
138
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced gastric or gastroesophageal junction cancer from JAVELIN solid tumor phase Ib trial: Analysis of safety and clinical activity.
First Author: Hyun Cheol Chung
Poster
2016 ASCO Annual Meeting
Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced cancer: safety data from 1300 patients enrolled in the phase 1b JAVELIN Solid Tumor trial.
First Author: Karen Kelly
Poster
2016 ASCO Annual Meeting
Avelumab (MSB0010718C; anti-PD-L1) as a first-line treatment for patients with advanced NSCLC from the JAVELIN Solid Tumor phase 1b trial: Safety, clinical activity, and PD-L1 expression.
First Author: Claire F. Verschraegen
Poster
2016 ASCO Annual Meeting
Avelumab (MSB0010718C; anti-PD-L1) in patients with metastatic urothelial carcinoma from the JAVELIN solid tumor phase 1b trial: Analysis of safety, clinical activity, and PD-L1 expression.
First Author: Andrea B. Apolo